Dry Age-Related Macular Degeneration Market, by Disease Type (Early AMD, Neovascular AMD, Geographic Atrophy AMD), by Diagnosis/Treatment (Optical Coherence Tomography (OCT), Fundoscopy, Fluorescein Angiography (FA), Intravitreal Injections) and, by End User (Hospitals, Specialized Clinics, Ambulatory Surgery Centers, Retinal Clinics): Opportunity Analysis and Industry Forecast, 2023-2032

The Dry age-related macular degeneration market report offers a comprehensive study on the global market size & forecast, segmental splits, and further classification into regional & country-level. Furthermore, it highlights the market dynamics & trends, Porters’ five force analysis, competitive landscape, and market share analysis.

Dry age-related macular degeneration market Revenue ($Million), By Segment, 2023 to 2032

Graph for representation purpose only

Segmental Outlook

The global Dry age-related macular degeneration market is segmented on the basis of by disease type, by diagnosis/treatment, by end user. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Spain, Italy, and rest of Europe), Asia-Pacific (China, Japan, Australia, South Korea, India, and rest of Asia-Pacific), and LAMEA (Latin America, the Middle East, and Africa).

The segmental analysis includes real-time and forecast in both qualitative and quantitative terms. This helps clients understand the most lucrative segments for investors to capitalize on in the market.

Dry age-related macular degeneration market Revenue ($Million), By Type, 2023 to 2032

Graph for representation purpose only

Competitive Scenario

The report includes an in-depth analysis of the major market players operating across the globe, along with an outlook on top player positioning. Furthermore, the report focuses on developmental strategies such as mergers & acquisitions, product/service launches, and collaborations adopted by the market players to maintain and enhance their foothold in the market.

Key players identified in this report are Novartis AG, Roche, AstraZeneca, F. Hoffmann-La Roche Ltd., Hoffman-La Roche, Inc., Merck and Co., Inc., Macular Photocoagulation Study Group, Otsuka America Pharmaceutical, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.

Report Coverage

• Market Size Projections: 2023 to 2032

• Major Segments Covered: by disease type, by diagnosis/treatment, by end user

• Market Dynamics and Trends

• Competitive Landscape Reporting

Note

• Clients have the liberty to customize the list as per their requirements.

• AMR offers 20% free customization policy and clients can request AMR for a tailor-made report by considering their requirements. However, the modification will be finalized post a quick feasibility check.

  Dry Age-Related Macular Degeneration Market Report Highlights

Aspects	Details
By Disease Type	Early AMD Neovascular AMD Geographic Atrophy AMD
By Diagnosis/Treatment	Optical Coherence Tomography (OCT) Fundoscopy Fluorescein Angiography (FA) Intravitreal Injections
By End User	Hospitals Specialized Clinics Ambulatory Surgery Centers Retinal Clinics
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players	Novartis AG, Otsuka America Pharmaceutical, Regeneron Pharmaceuticals, Sanofi S.A., Hoffman-La Roche, Macular Photocoagulation Study Group, Merck and Co., F. Hoffmann-La Roche Ltd., Roche, AstraZeneca

^*Terms and Conditions Apply